C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,245 | -32.5% | 90,992 | -0.2% | 0.00% | – |
| Q2 2023 | $250,685 | -79.2% | 91,158 | -76.3% | 0.00% | – |
| Q1 2023 | $1,207,656 | -48.7% | 384,604 | -3.6% | 0.00% | – |
| Q4 2022 | $2,354,288 | -29.7% | 399,032 | +4.5% | 0.00% | -100.0% |
| Q3 2022 | $3,350,000 | +19.9% | 381,983 | +3.1% | 0.00% | 0.0% |
| Q2 2022 | $2,793,000 | -67.0% | 370,520 | +6.1% | 0.00% | 0.0% |
| Q1 2022 | $8,474,000 | -27.2% | 349,262 | -3.4% | 0.00% | -50.0% |
| Q4 2021 | $11,648,000 | -28.4% | 361,696 | -0.6% | 0.00% | -33.3% |
| Q3 2021 | $16,261,000 | +41.7% | 363,953 | +20.0% | 0.00% | +50.0% |
| Q2 2021 | $11,479,000 | +160.6% | 303,379 | +154.8% | 0.00% | +100.0% |
| Q1 2021 | $4,405,000 | +6.3% | 119,076 | -4.8% | 0.00% | 0.0% |
| Q4 2020 | $4,144,000 | – | 125,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |